Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 3000 participants.

Also called NCT06492291

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06492291
  • EU CT 2023-504922-20-00
  • WHO UTN U1111-1290-3950
  • jRCT jRCT2051240110
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Singapore, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06492291. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-05 (actual); primary completion 2028-10-13 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Condition
Hypercholesterolemia
Intervention (Drug)
Enlicitide Decanoate
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct06492291
Content hash
ccb4e205b3f771780c6400bbf4b074b122d84e54d031feea31d9f61bebb7f8e6